A new cardiac diagnostic device aimed at helping physicians rule out active ischemia in patients presenting to the emergency department (ED) with chest pain is being trialled at five of the most respected research facilities in the United States (Mayo Clinic, Rochester, MN; Baylor University, Houston, TX; Vanderbilt University, Nashville, TN; University of Cincinnati, OH; andWake Forest University, Winston-Salem, NC).
The device, developed by Creavo Medical Technologies Ltd a UK-based privately-held medical device company, is a mobile medical magnetometer which can be used at a patient’s bedside to measure and report electromagnetic fluctuations caused by heart activity.
Approximately 720 patients will be enrolled throughout the trial, which is the largest magnetocardiography (MCG) trial ever to take place in the United States and is scheduled to be completed by mid-2019.
Gregory J. Fermann, MD, Professor, Executive Vice Chairman and Director of the Clinical Trials Centre at the University of Cincinnati said: “Each year, 8 to 10 million patients complaining of chest pain present to an emergency department (ED) in the United States”.
“The ability to quickly risk stratify and safely discharge ED patients presenting with symptoms consistent with chest pain of cardiac origin is critically important to the overall flow of patients through crowded Emergency Departments. This device has the potential to become an essential tool in the rapid evaluation of these patients.”
“On behalf of the entire MAGNET ACS-US investigative team, I am excited to report that we are open to recruitment of Emergency Department (ED) patients.”
Steve Parker, Chief Executive Officer at Creavo said: “Our device has the potential to tackle a global unmet need. Non-ischemic chest pain patients place a huge strain on emergency departments as the current rule-out triage process of electrocardiograms and blood biomarker tests can take a number of hours. Our device is designed to rapidly aid physicians with the decision to rule out acute coronary syndrome by performing a non-invasive five-minute scan, freeing up resources and bed space.”
